Indium (111In) satumomab pendetide

(Redirected from MAb B72.3) Monoclonal antibody Pharmaceutical compound

Indium (In) satumomab pendetide
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	TAG-72
Clinical data
Other names	MAb B72.3-GYK-DTPA
ATC code	V09IB02 (WHO)
Identifiers
CAS Number	138955-27-8 144058-40-2
ChemSpider	none
UNII	7V9926378A
(what is this?) (verify)

Indium (In) satumomab pendetide (trade name OncoScint CR103) is a mouse monoclonal antibody which is used for cancer diagnosis. The antibody, satumomab, is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111.

References

García-Fernández R, Luna-Pérez P, Hernández-Hernández DM, Iwasaki-Otake L, Pichardo-Romero P, Rodríguez-Ramirez S (2002). "". Gaceta Médica de México. 138 (2): 139–44. PMID 12001423.

External links

Drugs.com Satumomab pendetide

Diagnostic radiopharmaceuticals (V09)

Central nervous system

Tc (Exametazime, Pentetic acid)
I (Ioflupane (123I)
Iofetamine (123I)
Iolopride (123I)
Iomazenil)
F (Florbetapir (18F), Flutemetamol (18F))

Skeletal system

Tc (Medronic acid)

Renal

Gastrointestinal/Hepatic

Se (SeHCAT)

Respiratory system

Cardiovascular system

Inflammation/infection

Tumor

Tc
In
- Capromab pendetide
- Satumomab pendetide
I (Minretumomab)
I (Iobenguane (123I))
I (Iobenguane (131I))
F
Cu
- Dotatate
Piflufolastat (18F)

Adrenal cortex

I
I / I (Iodocholesterol)

Radionuclides
(including tracers)

positron (PET list)

C (ME@HAPTHI)
25B-NBOMe (Cimbi-36)
Acetate
Choline
Carfentanil
DASB
DTBZ
Flumazenil
Methionine
N-Methylspiperone
Pittsburgh compound B
Raclopride
Verapamil)
N
- Ammonia
Cu
Desmethoxyfallypride
Fallypride
Florbetaben (18F)
Florbetapir (18F)
Flortaucipir (18F)
Flotufolastat F-18
Flubatine
Fluciclovine
Fludeoxyglucose (18F) (FDG)-glucose analogue
Flumazenil
F (Altanserin)
Fluorocholine
Fluorodeoxysorbitol (FDS)
Fluorodopa
Fluoroestradiol F-18
Fluorothymidine F-18
Flurpiridaz (18F)
Fluspidine
Flutemetamol
FMISO
Gallium (Ga) gozetotide
Ga
Mefway
MPPF
N-Methylspiperone
Nifene
FET
O (Water)
Piflufolastat F-18
Rb (Rubidium chloride)
Setoperone)

gamma ray/photon (SPECT/scintigraphy)

Isotopes used:

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab Amivantamab Ascrinvacumab Atezolizumab (+hyaluronidase) Balstilimab Botensilimab Cixutumumab Conatumumab Cosibelimab Daratumumab Drozitumab Duligotumab Dusigitumab Enfortumab vedotin Enoticumab Figitumumab Flanvotumab Ganitumab Glembatumumab vedotin Intetumumab Ipilimumab Iratumumab Istiratumab Icrucumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Nesvacumab Nivolumab (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab Panitumumab Patritumab Pembrolizumab Pritumumab Radretumab Ramucirumab Rilotumumab Robatumumab Seribantumab Sugemalimab Tarextumab Tisotumab vedotin Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab Bavituximab Brentuximab vedotin Carotuximab Cetuximab Derlotuximab biotin Dinutuximab Ecromeximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine Brontictuzumab Cantuzumab mertansine Cantuzumab ravtansine Cirmtuzumab Citatuzumab bogatox Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab Demcizumab Dalotuzumab Denintuzumab mafodotin Elotuzumab Emactuzumab Emibetuzumab Enoblituzumab Epcoritamab Etaracizumab Farletuzumab Ficlatuzumab Flotetuzumab Gemtuzumab ozogamicin Glofitamab Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lifastuzumab vedotin Lintuzumab Lorvotuzumab mertansine Lumretuzumab Matuzumab Milatuzumab Naxitamab Nimotuzumab Obinutuzumab Ocaratuzumab Odronextamab Otlertuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Pinatuzumab vedotin Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine Sacituzumab govitecan Sibrotuzumab Simtuzumab Sofituzumab vedotin Tacatuzumab tetraxetan Tigatuzumab Trastuzumab (+deruxtecan / +emtansine) Tucotuzumab celmoleukin Vandortuzumab vedotin Vanucizumab Veltuzumab Vorsetuzumab mafodotin Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab
Chimeric + humanized	Depatuxizumab mafodotin Duvortuxizumab Ontuxizumab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This nuclear medicine article is a stub. You can help Misplaced Pages by expanding it.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: